Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced that CEO Tiago Reis Marques will present at NobleCon18 on April 21, 2022, at 12:30 p.m. ET in Hollywood, FL. The company focuses on developing new treatments for psychiatric and neurological disorders and offers access to IV ketamine infusions for patients with mental illness. This presentation will highlight Pasithea's innovative approaches and commitment to addressing mental health needs.
- None.
- None.
MIAMI BEACH, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced its Chief Executive Officer, Tiago Reis Marques, will present at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference in Hollywood, FL, as follows:
| Date: | Thursday, April 21, 2022 |
| Time: | 12:30 p.m. ET |
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When is Pasithea Therapeutics presenting at NobleCon18?
What is the focus of Pasithea Therapeutics?
Who is the CEO of Pasithea Therapeutics?
What is the stock symbol for Pasithea Therapeutics?
